- £701.05m
- £678.05m
- £145.26m
Annual income statement for Ergomed, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 54.1 | 68.3 | 86.4 | 119 | 145 |
| Cost of Revenue | |||||
| Gross Profit | 19.3 | 29.5 | 39.6 | 48.4 | 59.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 64.6 | 62.7 | 72.9 | 104 | 126 |
| Operating Profit | -10.4 | 5.52 | 13.5 | 14.6 | 18.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -10.8 | 4.99 | 12.6 | 14.3 | 18 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.98 | 5.57 | 9.68 | 12.7 | 15 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.98 | 5.57 | 9.68 | 12.7 | 15 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.98 | 5.57 | 9.68 | 12.7 | 15 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.064 | 0.147 | 0.205 | 0.341 | 0.321 |